1. Introduction and Background
Human chorionic gonadotropin (hCG) is a heterodimeric glycoprotein hormone produced principally by syncytiotrophoblast cells of the placenta following embryo implantation. First identified in the early twentieth century through its capacity to induce ovulation in animal bioassays, hCG has since emerged as one of the most extensively studied hormones in reproductive endocrinology. Its detection in maternal serum and urine forms the biochemical basis of modern pregnancy testing, yet the physiological roles of hCG extend well beyond this diagnostic application, encompassing luteal maintenance, steroidogenic regulation, immune modulation, and angiogenic signalling (Cole, 2010). The hormone belongs to the glycoprotein hormone family that also includes luteinising hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH), all of which share a common alpha subunit but differ in their hormone-specific beta subunits (Casarini et al., 2018).
Research interest in hCG has intensified over the past two decades as advances in structural biology, receptor pharmacology, and glycoprotein biochemistry have revealed that hCG is not a single molecular entity but rather a family of related glycoforms with distinct biological activities. These variants, produced by trophoblastic tissue at different stages of gestation and by certain neoplastic tissues, differ in their carbohydrate moieties, receptor binding kinetics, and downstream signalling profiles (Fournier, Guibourdenche and Evain-Brion, 2015). This molecular heterogeneity has significant implications for the interpretation of both diagnostic assays and experimental research findings.
2. Molecular Structure and Glycoform Variants
2.1 Alpha-Beta Subunit Architecture
The hCG heterodimer comprises a 92-amino-acid common alpha subunit (shared with LH, FSH, and TSH) and a 145-amino-acid hormone-specific beta subunit (hCG-beta). The crystal structure, resolved at 2.6 angstrom resolution, revealed that both subunits adopt a cystine knot fold — a structural motif characterised by three disulphide bonds in which two bonds form a ring through which the third passes (Lapthorn et al., 1994). This architecture is shared across the glycoprotein hormone family and confers considerable thermodynamic stability. The alpha subunit contains two N-linked glycosylation sites (Asn-52 and Asn-78), whilst the beta subunit contains two N-linked sites (Asn-13 and Asn-30) and four O-linked glycosylation sites within a carboxy-terminal peptide extension unique to hCG-beta. This C-terminal peptide (CTP), comprising approximately 30 amino acids, is absent from the LH beta subunit and is largely responsible for the prolonged circulating half-life of hCG (approximately 24-36 hours) compared with LH (approximately 20 minutes).
2.2 Glycosylation and Molecular Heterogeneity
The carbohydrate content of hCG constitutes approximately 25-30% of its molecular mass and plays a critical role in protein folding, heterodimer assembly, receptor binding, and metabolic clearance. Different tissue sources and gestational stages produce hCG variants with markedly different glycan profiles. Regular hCG, secreted predominantly during weeks 3-10 of gestation, carries complex-type biantennary N-glycans with terminal sialic acid residues. Hyperglycosylated hCG (hCG-H), the predominant form in early pregnancy (weeks 3-5), bears larger triantennary and tetrantennary N-glycans with increased fucosylation (Fournier, Guibourdenche and Evain-Brion, 2015). The functional significance of this glycoform diversity has been a subject of active investigation, with evidence suggesting that hCG-H acts primarily through autocrine/paracrine mechanisms on trophoblast invasion rather than through classical LH/CG receptor signalling (Cole, 2010).
3. Receptor Pharmacology and Signal Transduction
3.1 The LH/CG Receptor
Both hCG and LH exert their biological effects through the luteinising hormone/choriogonadotropin receptor (LHCGR), a class A G protein-coupled receptor (GPCR) encoded by a single gene on chromosome 2p21. The LHCGR possesses a large extracellular domain (ECD) of approximately 340 amino acids containing leucine-rich repeats that form the primary hormone-binding interface, connected to a seven-transmembrane domain typical of the rhodopsin-like GPCR superfamily (Dufau, 1998). Despite binding the same receptor, hCG and LH display quantitative differences in their binding and signalling characteristics. hCG exhibits approximately 2-fold higher binding affinity for the LHCGR compared with LH, and its extended plasma half-life results in more sustained receptor occupation and downstream pathway activation (Casarini et al., 2018).
3.2 Intracellular Signalling Cascades
Ligand binding to the LHCGR activates multiple intracellular signalling pathways. The canonical pathway involves coupling to the stimulatory G protein (Gs-alpha), leading to activation of adenylyl cyclase and elevation of intracellular cyclic adenosine monophosphate (cAMP) concentrations. This cAMP signal activates protein kinase A (PKA), which phosphorylates transcription factors including the steroidogenic factor 1 (SF-1) and cAMP response element-binding protein (CREB), ultimately driving expression of steroidogenic enzymes such as StAR (steroidogenic acute regulatory protein), CYP11A1 (cholesterol side-chain cleavage enzyme), and CYP17A1 (17-alpha-hydroxylase/17,20-lyase) (Dufau, 1998). At higher concentrations, LHCGR activation also engages Gq/11-mediated phospholipase C (PLC) signalling, generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which mobilise intracellular calcium and activate protein kinase C (PKC), respectively. Notably, comparative studies have suggested that hCG and LH may exhibit biased agonism at the LHCGR, with hCG favouring cAMP/PKA signalling and LH displaying relatively greater activation of extracellular signal-regulated kinase (ERK) pathways (Riccetti et al., 2017). Activating and inactivating mutations of the LHCGR have provided further insight into receptor-effector coupling mechanisms and their physiological consequences (Themmen and Huhtaniemi, 2000).
4. Reproductive Biology and Steroidogenesis Research
4.1 Corpus Luteum Maintenance and Progesterone Production
The most well-characterised physiological role of hCG is the rescue and maintenance of the corpus luteum during early pregnancy. In the absence of conception, the corpus luteum undergoes luteolysis approximately 14 days after ovulation due to declining LH pulse frequency. Following implantation, rapidly rising hCG concentrations from the developing syncytiotrophoblast bind to LHCGR on luteal cells, stimulating continued progesterone biosynthesis and preventing luteal regression. This "luteal rescue" is essential for maintaining the secretory endometrium during the critical period before the placenta assumes sufficient progesterone production (the luteal-placental shift, occurring at approximately weeks 7-9 of gestation) (Cole, 2010). Experimental studies have demonstrated that immunoneutralisation of hCG in early pregnancy models leads to progesterone decline and pregnancy failure, confirming the non-redundant nature of this luteotrophic function.
4.2 Leydig Cell Stimulation and Testicular Function
In the male gonad, hCG acts on LHCGR-expressing Leydig cells located in the testicular interstitium. Leydig cells represent the primary source of testicular testosterone, and their stimulation by LH (or exogenous hCG) constitutes the principal regulatory mechanism for androgen biosynthesis. hCG binding activates the cAMP/PKA cascade, upregulating StAR-mediated cholesterol transport to the inner mitochondrial membrane and stimulating the enzymatic conversion of cholesterol to pregnenolone, and subsequently to testosterone through the delta-4 or delta-5 steroidogenic pathways (Dufau, 1998). In vitro studies using primary Leydig cell cultures have demonstrated dose-dependent testosterone production in response to hCG stimulation, with maximal steroidogenic responses observed at concentrations that saturate LHCGR occupancy (Riccetti et al., 2017).
The hCG stimulation test has been utilised in research settings to assess Leydig cell functional reserve and to investigate conditions characterised by impaired testicular steroidogenesis. In developmental biology research, fetal Leydig cell responses to hCG stimulation have been studied in the context of sexual differentiation, where testosterone production during critical developmental windows drives virilisation of the male urogenital tract. The LHCGR knockout mouse model has been instrumental in delineating the consequences of absent gonadotropin receptor signalling, demonstrating infertility, Leydig cell hypoplasia, and markedly reduced androgen production in affected males (Themmen and Huhtaniemi, 2000).
5. Angiogenesis and Vascular Remodelling
Beyond its classical endocrine roles, hCG has been identified as a potent pro-angiogenic factor. This property is of particular relevance in the context of early pregnancy, where extensive vascular remodelling of the uterine vasculature is required to support placental development and embryonic growth. Studies have demonstrated that hCG stimulates proliferation and tubulogenesis of endothelial cells in vitro, and that these effects are mediated, at least in part, through LHCGR expressed on vascular endothelium . hCG-induced angiogenesis involves upregulation of vascular endothelial growth factor (VEGF) expression and modulation of angiopoietin signalling, establishing a pro-angiogenic milieu within the developing decidua .
The corpus luteum itself is among the most highly vascularised structures in the body, and luteal angiogenesis is critical for adequate progesterone output. Research has established that hCG-driven VEGF production within the corpus luteum is a key mediator of the luteal vascular network that sustains early pregnancy. Furthermore, the identification of LHCGR expression in extragonadal tissues — including uterine vasculature, mammary epithelium, and certain immune cell populations — has expanded the scope of potential hCG actions beyond the classical gonadal axis .
6. Pregnancy Maintenance and Immunomodulation
The successful establishment of pregnancy requires tolerance of the semi-allogeneic fetal-placental unit by the maternal immune system. Emerging research has implicated hCG as a participant in the immunological adaptations that characterise the maternal-fetal interface. Experimental evidence suggests that hCG influences the phenotype and function of uterine natural killer (uNK) cells, promoting a tolerogenic rather than cytotoxic profile. Additionally, hCG has been reported to modulate T-regulatory cell populations at the decidual level and to influence cytokine networks that govern implantation receptivity (Cole, 2010).
The hyperglycosylated variant of hCG (hCG-H) has attracted particular interest in implantation biology. Unlike regular hCG, which functions primarily as an endocrine hormone acting on distant LHCGR-expressing tissues, hCG-H appears to operate through autocrine and paracrine mechanisms at the implantation site. Studies have demonstrated that hCG-H promotes trophoblast invasion of the decidualised endometrium — a process essential for establishing adequate placental anchorage and vascular access. Low circulating concentrations of hCG-H in early pregnancy have been associated with implantation failure in research cohorts, although the precise receptor or signalling pathway through which hCG-H acts remains the subject of ongoing investigation (Fournier, Guibourdenche and Evain-Brion, 2015).
7. Current Research Directions
7.1 Biased Agonism and Receptor Selectivity
A significant area of contemporary research concerns the concept of biased agonism at the LHCGR. Although hCG and LH bind the same receptor, accumulating evidence indicates that these ligands stabilise distinct receptor conformations that preferentially activate different intracellular signalling pathways. In vitro studies comparing the signalling profiles of hCG and LH in mouse Leydig cells have demonstrated equivalent testosterone output despite differential activation of early signalling intermediaries, including cAMP accumulation kinetics and ERK phosphorylation dynamics (Riccetti et al., 2017). Understanding the molecular determinants of this biased agonism — including the contributions of the CTP, glycan composition, and receptor dwell time — represents an active frontier in glycoprotein hormone pharmacology (Casarini et al., 2018).
7.2 Extragonadal LHCGR Expression
The discovery of functional LHCGR expression in non-gonadal tissues has opened new avenues of investigation into the broader physiological roles of hCG signalling. LHCGR transcripts and protein have been identified in the uterus, fallopian tubes, mammary gland, adrenal cortex, skin, brain, and various immune cell lineages . The functional significance of extragonadal LHCGR signalling is under active investigation, with preclinical studies suggesting roles in endometrial receptivity, myometrial quiescence, and tissue-specific immunoregulation. These observations have prompted exploration of hCG-based research in contexts beyond classical reproductive endocrinology, including wound healing, where hCG-stimulated angiogenesis may contribute to tissue repair processes .
7.3 Glycoform-Specific Functions
The recognition that different hCG glycoforms possess distinct biological activities has prompted investigation into glycoform-specific receptor interactions and signalling outcomes. Current research efforts are directed toward characterising the structure-activity relationships governing glycan-mediated differences in LHCGR binding, internalisation kinetics, and downstream pathway selection. Advances in glycoprotein engineering and mass spectrometric glycan analysis are enabling more precise dissection of these relationships than was previously possible (Fournier, Guibourdenche and Evain-Brion, 2015).
8. Conclusion
Human chorionic gonadotropin represents a structurally complex glycoprotein hormone whose biological activities extend well beyond its established role as a pregnancy biomarker. Research spanning several decades has elucidated the molecular architecture of the alpha-beta heterodimer, characterised the signalling cascades initiated by LHCGR activation, and delineated distinct roles for hCG in luteal maintenance, Leydig cell steroidogenesis, angiogenesis, and immunomodulation at the maternal-fetal interface. The identification of molecular heterogeneity among hCG glycoforms and the discovery of extragonadal LHCGR expression have broadened the scope of hCG research, revealing a signalling system of considerably greater complexity than initially appreciated. Contemporary investigations into biased agonism, glycoform-specific functions, and non-classical tissue targets continue to refine understanding of this hormone and its potential applications in experimental biology.